Bolt Biotherapeutics Company Insiders
| BOLT Stock | USD 6.71 0.76 12.77% |
Bolt Biotherapeutics employs about 52 people. The company is managed by 14 executives with a total tenure of roughly 122 years, averaging almost 8.0 years of service per executive, having 3.71 employees per reported executive. Breaking down Bolt Biotherapeutics' management performance can provide insight into the firm performance.
Bolt Biotherapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Bolt Biotherapeutics' future performance. Based on our forecasts, it is anticipated that Bolt will maintain a workforce of slightly above 70 employees by August 2025.Bolt Biotherapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.3457) % which means that it has lost $0.3457 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8392) %, meaning that it created substantial loss on money invested by shareholders. Bolt Biotherapeutics' management efficiency ratios could be used to measure how well Bolt Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.67 in 2025. Return On Capital Employed is likely to drop to -0.92 in 2025. At this time, Bolt Biotherapeutics' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 142.4 M in 2025, whereas Non Current Liabilities Other is likely to drop slightly above 36.8 K in 2025.Common Stock Shares Outstanding is likely to drop to about 30.9 M in 2025. Net Loss is likely to drop to about (83.3 M) in 2025
Bolt Biotherapeutics Workforce Comparison
Bolt Biotherapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 682. Bolt Biotherapeutics holds roughly 52.0 in number of employees claiming about 8% of equities under Health Care industry.
Bolt Biotherapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bolt Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bolt Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Bolt Biotherapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-06-01 | 0.875 | 7 | 8 | 154,000 | 263,521 |
| 2023-12-01 | 0.0833 | 2 | 24 | 10,000 | 289,454 |
| 2022-12-01 | 4.0 | 4 | 1 | 112,261 | 0.00 |
| 2021-12-01 | 1.75 | 7 | 4 | 124,740 | 35,714 |
| 2021-03-01 | 0.8654 | 45 | 52 | 18,199,386 | 19,707,611 |
Bolt Biotherapeutics Notable Stakeholders
A Bolt Biotherapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Bolt Biotherapeutics often face trade-offs trying to please all of them. Bolt Biotherapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Bolt Biotherapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| William Quinn | CFO Secretary | Profile | |
| Wesley Burwell | VP Resources | Profile | |
| Randall Schatzman | CEO Director | Profile | |
| Justin Kenkel | Senior Scientist | Profile | |
| Edith MD | Chief Officer | Profile | |
| Michael Alonso | Senior Research | Profile | |
| MBA CFA | Chief Officer | Profile | |
| Ming Yin | VP Biometrics | Profile | |
| Bruce MD | Sr Medicine | Profile | |
| Edgar MD | Founder Director | Profile | |
| Nathan Ihle | Senior Operations | Profile | |
| PharmD BCOP | Senior Development | Profile | |
| Karen Bergman | VP Relations | Profile | |
| Sarah Nemec | Senior Officer | Profile |
About Bolt Biotherapeutics Management Performance
The success or failure of an entity such as Bolt Biotherapeutics often depends on how effective the management is. Bolt Biotherapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Bolt management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Bolt management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.63) | (0.67) | |
| Return On Capital Employed | (0.87) | (0.92) | |
| Return On Assets | (0.63) | (0.67) | |
| Return On Equity | (1.10) | (1.05) |
Please note, the imprecision that can be found in Bolt Biotherapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Bolt Biotherapeutics. Check Bolt Biotherapeutics' Beneish M Score to see the likelihood of Bolt Biotherapeutics' management manipulating its earnings.
Bolt Biotherapeutics Workforce Analysis
Traditionally, organizations such as Bolt Biotherapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Bolt Biotherapeutics within its industry.Bolt Biotherapeutics Manpower Efficiency
Return on Bolt Biotherapeutics Manpower
| Revenue Per Employee | 147.9K | |
| Revenue Per Executive | 549.3K | |
| Net Loss Per Employee | 1.2M | |
| Net Loss Per Executive | 4.5M | |
| Working Capital Per Employee | 672.3K | |
| Working Capital Per Executive | 2.5M |
Additional Tools for Bolt Stock Analysis
When running Bolt Biotherapeutics' price analysis, check to measure Bolt Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bolt Biotherapeutics is operating at the current time. Most of Bolt Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bolt Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bolt Biotherapeutics' price. Additionally, you may evaluate how the addition of Bolt Biotherapeutics to your portfolios can decrease your overall portfolio volatility.